ABSTRACT:
Peptide therapeutics are a fast-growing class of medicines, but traditional solid phase peptide synthesis (SPPS) has limitations in cost, scalability, and environmental impact. Pfenex Expression Technology® (Pfenex) provides an alternative by using a tailored collection of small, highly expressed Pseudomonas fluorescens proteins as fusion partners to enable efficient recombinant peptide production. Potential fusion constructs are evaluated using Pfenex’s modular screening tools to maximize expression levels, followed by site specific enzymatic cleavage to liberate the desired peptide. This manufacturing strategy has been clinically proven and commercialized for teriparatide, demonstrating strong yields and regulatory approval. Collectively, the Pfenex platform establishes recombinant production as a viable, sustainable, and competitive approach for large scale peptide manufacturing.